Eirini Katodritou, Efstathios Kastritis, Moshe Gatt, Yael C Cohen, Irit Avivi, Anastasia Pouli, Chrysavgi Lalayianni, Noa Lavi, Sosana Delimpasis, Marie-Christine Kyrtsonis, Michalis Michael, Celia Suriu, Zektser Miri, Katrin Tzafarti, Chrysanthi Vadikoliou, Dimitris Maltezas, Panagiotis Zikos, Chezi Ganzel, Yuliana Vaxman, Ariel Aviv, Anna Christoforidou, Maria Gavriatopoulou, Adir Shaulov, Evgenia Verrou, Aristea-Maria Papanota, Gabriel Fakinos, Annita-Ioanna Gkioka, Vasiliki Palaska, Theodora Triantafyllou, Pavlina Konstantinidou, Achilles Anagnostopoulos, Evangelos Terpos, Meletios A Dimopoulos
We investigated incidence, characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) treated mainly with novel therapies. Based on definition (BMPCs <20% and lytic lesions/plasmacytomas, without anemia, renal insufficiency or hypercalcemia) we identified 140 patients with MFMM, among 4650 myeloma patients (3%). Twice the number of patients with typical myeloma were used as controls; 60% were <65 years and 70% had advanced bone disease. Plasmacytomas were more frequent in MFMM compared with standard myeloma (68% vs 15%, P < ...
May 2020: American Journal of Hematology